Incyte Q2 2026 earnings and MPN pipeline update drive PRLD
Incyte Q2 2026 earnings and MPN pipeline update drive PRLD premarket surge
- PRLD gained ~16.76% in premarket on July 28, 2026 after closing ~$3.89 on July 27.
- Incyte (INCY) released Q2 2026 results and held earnings call this morning, directly linked to PRLD move on social media.
- Prelude signed 2025 option agreement with Incyte for mutant-selective JAK2V617F inhibitor PRT12396 in myeloproliferative neoplasms (MPNs).
- PRT12396 Phase 1 enrollment initiated in 2026 for polycythemia vera and myelofibrosis per Prelude's May update.
- Positive Incyte commentary on JAK2V617F/MPN progress or collaboration implied as catalyst; Incyte has parallel JAK2 program (INCB160058).
- No new press release from Prelude (latest May 2026 Q1 results and program updates); recent analyst coverage and filings noted but not primary driver.
- Prior July estimate cuts weighed on stock; today's move reflects renewed interest in MPN pipeline partnership.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.